Predicting overall survival in patients with metastatic melanoma on antiangiogenic therapy and recist stable disease on initial posttherapy images using ct texture analysis

American Journal of Roentgenology

Volumn 205, Issue 3, 2015, Pages W283-W293

  Smith, Andrew D ^a   Gray, Mark R ^a   Del Campo, Sara Martin ^b   Shlapak, Darya ^a   Ganeshan, Balaji ^c   Zhang, Xu ^a   Carson, William E ^b  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Antiangiogenic therapy; Biomarker; CT texture analysis; Metastatic melanoma

Indexed keywords

ALKALINE PHOSPHATASE; BEVACIZUMAB; LACTATE DEHYDROGENASE; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; IMAGE ANALYSIS; IMAGE QUALITY; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METASTATIC MELANOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SURVIVAL RATE; TUMOR VOLUME; AGED; CANCER STAGING; CLINICAL TRIAL; CONTROLLED STUDY; MELANOMA; MIDDLE AGED; PHASE 2 CLINICAL TRIAL; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; RADIOGRAPHY; RANDOMIZED CONTROLLED TRIAL; SECONDARY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84942597190     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.15.14315     Document Type: Article

References (26)

1. Grignol VP, Olencki T, Relekar K, et al. A phase 2 trial of bevacizumab and high-dose interferon alpha 2b in metastatic melanoma. J Immunother 2011; 34:509-515
2. Perez DG, Suman VJ, Fitch TR, et al. Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unrespectable stage IV melanoma. Cancer 2009; 115:119-127
3. Cao-González M, Viteri S, Díaz-Lagares A, et al. Preliminary results of the combination of bevacizumab and weekly paclitaxel in advanced melanoma. Oncology 2008; 74:12-16
4. Varker KA, Biber JE, Kefauver C, et al. A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma. Ann Surg Oncol 2007; 14:2367-2376
5. Einspahr JG, Thomas TL, Saboda K, et al. Expression of vascular endothelial growth factor in early cutaneous melanocytic lesion progression. Cancer 2007; 110:2519-2527
6. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9:669-676
7. Balch CM, Gershenwald JE, Thompson JF, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27:6199-6206
8. Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007; 25:1753-1759
9. Choi H. Response evaluation of gastrointestinal stromal tumors. Oncologist 2008; 13(suppl 2):4-7
10. Benjamin RS, Choi H, Macapinlac HA, et al. We should desist using RECIST, at least in GIST. J Clin Oncol 2007; 25:1760-1764
11. Smith AD, Shah SN, Rini BI, Lieber ML, Remer EM. Utilizing pre-therapy clinical schema and initial CT changes to predict progression-free survival in patients with metastatic renal cell carcinoma on VEGF-targeted therapy: a preliminary analysis. Urol Oncol 2013; 31:1283-1291
12. Smith AD, Lieber ML, Shah SN. Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT. AJR 2010; 194:157-165
13. Smith AD, Shah SN, Rini BL, Remer EM. Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy. AJR 2010; 194:1470-1478
14. Gray MR, Martin del Campo S, Zhang X, et al. Metastatic melanoma: lactate dehydrogenase levels and CT imaging findings of tumor devascularization allow accurate prediction of survival in patients treated with bevacizumab. Radiology 2014; 270:425-434
15. Krajewski KM, Nishino M, Franchetti Y, Ramaiya NH, Van den Abbeele AD, Choueiri TK. Intraobserver and interobserver variability in computed tomography size and attenuation measurements in patients with renal cell carcinoma receiving antiangiogenic therapy: implications for alternative response criteria. Cancer 2014; 120:711-721
16. Goh V, Ganeshan B, Nathan P, Juttla JK, Vinayan A, Miles KA. Assessment of response to tyrosine kinase inhibitors in metastatic renal cell cancer: CT texture as a predictive biomarker. Radiology 2011; 261:165-171
17. Zhang H, Graham CM, Elci O, et al. Locally advanced squamous cell carcinoma of the head and neck: CT texture and histogram analysis allow independent prediction of overall survival in patients treated with induction chemotherapy. Radiology 2013; 269:801-809
18. Ganeshan B, Panayiotou E, Burnand K, Dizdarevic S, Miles K. Tumour heterogeneity in non-small cell lung carcinoma assessed by CT texture analysis: a potential marker of survival. Eur Radiol 2012; 22:796-802
19. Ganeshan B, Skogen K, Pressney I, Coutroubis D, Miles K. Tumour heterogeneity in oesophageal cancer assessed by CT texture analysis: preliminary evidence of an association with tumour metabolism, stage, and survival. Clin Radiol 2012; 67:157-164
20. Ganeshan B, Goh V, Mandeville HC, Ng QS, Hoskin PJ, Miles KA. Non-small cell lung cancer: histopathologic correlates for texture parameters at CT. Radiology 2013; 266:326-336
21. Miles KA, Ganeshan B, Griffiths MR, Young RC, Chatwin CR. Colorectal cancer: texture analysis of portal phase hepatic CT images as a potential marker of survival. Radiology 2009; 250:444-452
22. Miles KA, Ganeshan B, Hayball MP. CT texture analysis using the filtration-histogram method: what do the measurements mean? Cancer Imaging 2013; 13:400-406
23. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228-247
24. Nishino M, Jagannathan JP, Ramaiya NH, Van den Abbeele AD. Revised RECIST guideline version 1.1: what oncologists want to know and what radiologists need to know. AJR 2010; 195:281-289
25. Ng F, Kozarski R, Ganeshan B, Goh V. Assessment of tumor heterogeneity by CT texture analysis: can the longest cross-sectional area be used as an alternative to whole tumor analysis? Eur J Radiol 2013; 82:342-348
26. Miles KA, Ganeshan B, Rodriquez-Justo M, et al. Multifunctional imaging signature for V-KI-RAS2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations in colorectal cancer. J Nucl Med 2014; 55:386-391